Avery Dennison has launched AD Procerta, a new laboratory and testing facility service set to transform how the pharmaceutical industry navigates the complex world of label material testing.
Many variables are involved when creating labels for pharmaceutical products, such as medications, which need to be executed and applied perfectly for patient safety. Understanding the numerous legal and regulatory requirements and how labels will perform in specific environments to ensure that the labels are robust enough to meet the demands of the end-user. According to Avery Dennison, countless factors need to be considered. Pharmaceutical packaging engineers and brand owners now have access to a service to simplify and streamline this process.
‘We identified a market need,’ said Benoît Jourde, senior manager of new growth platforms for Europe at Avery Dennison. ‘It is a market need that is not really fulfilled at the moment. Although there are some excellent third-party laboratories out there, they are either missing the expertise specifically on self-adhesive labels, or they have extremely long lead times.
That's where Avery Dennison's long-standing history in materials science, combined with AD Procerta’s fresh, independent and reliable approach, can prove valuable. It speeds up the process, provides fact-based information, and offers facilities to accommodate specific testing methods.
Leiden Bio Science Park in the Netherlands is home to AD Procerta's state-of-the-art laboratory, which provides access to a wide range of testing capabilities.
‘A variety of label-specific tests can be performed at the facility with the guidance of an expert team to determine whether a label material is suitable for a given application,’ commented Jos van Noort, principal scientist for global pharma innovations at Avery Dennison.
‘We simulate real-world conditions in our laboratories and narrow down the options for testing materials,’ added Benoît. ‘It offers customers a number of choices that have all been thoroughly tested in real-life scenarios, allowing them to compare and contrast the options fairly.’
A few big pharmaceutical companies have piloted the service over the last two years to launch it this year.
‘Having learned from these pilot customers, we're now working with more than five large pharma companies and a few smaller ones as well,’ concluded Benoit.